Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Allred

Showing results (51-60 of 78) with videos related to

Pageof 8
Sort By:
Journal of the National Cancer Institute|August 19, 1999
Loss of heterozygosity at D14S62 and metastatic potential of breast cancerP O'Connell, K Fischbach, S Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patientsJ Chang, T J Powles, D C Allred, et al.
Human Pathology|March 13, 1998
Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinomaM L Gulley, M P Burton, D C Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patientsR C Zellars, S G Hilsenbeck, G M Clark, et al.
Breast Cancer Research and Treatment|April 17, 1999
Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot studyA Makris, T J Powles, D C Allred, et al.
International Journal of Cancer|February 7, 2001
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group StudyR M Elledge, S Green, R Pugh, et al.
American Journal of Clinical Oncology|March 10, 2001
Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192)D L Page, R Gray, D C Allred, et al.
Science (New York, N.Y.)|November 3, 1995
Aberrant subcellular localization of BRCA1 in breast cancerY Chen, C F Chen, D J Riley, et al.
Journal of the National Cancer Institute|February 3, 1993
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancerD C Allred, G M Clark, R Elledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1996
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patientsS Oesterreich, S G Hilsenbeck, D R Ciocca, et al.
Pageof 8

Showing results (51-60 of 78) with videos related to

Sort By:
Pageof 8
Journal of the National Cancer Institute|August 19, 1999
Loss of heterozygosity at D14S62 and metastatic potential of breast cancerP O'Connell, K Fischbach, S Hilsenbeck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 26, 2000
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patientsJ Chang, T J Powles, D C Allred, et al.
Human Pathology|March 13, 1998
Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinomaM L Gulley, M P Burton, D C Allred, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2000
Prognostic value of p53 for local failure in mastectomy-treated breast cancer patientsR C Zellars, S G Hilsenbeck, G M Clark, et al.
Breast Cancer Research and Treatment|April 17, 1999
Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot studyA Makris, T J Powles, D C Allred, et al.
International Journal of Cancer|February 7, 2001
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group StudyR M Elledge, S Green, R Pugh, et al.
American Journal of Clinical Oncology|March 10, 2001
Prediction of node-negative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192)D L Page, R Gray, D C Allred, et al.
Science (New York, N.Y.)|November 3, 1995
Aberrant subcellular localization of BRCA1 in breast cancerY Chen, C F Chen, D J Riley, et al.
Journal of the National Cancer Institute|February 3, 1993
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancerD C Allred, G M Clark, R Elledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 1, 1996
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patientsS Oesterreich, S G Hilsenbeck, D R Ciocca, et al.
Pageof 8